New golden era of chelation therapy in thalassaemia: The achievement and maintenance of normal range body iron stores

British Journal of Haematology

Volumn 150, Issue 4, 2010, Pages 489-490

  Kolnagou, Annita ^a,b   Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute Science Technology Environment and Medicine   (Cyprus)

^b Paphos General Hospital   (Cyprus)

Author keywords

combination therapy; deferiprone; deferoxamine; normalization of iron stores; thalassaemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

CHELATION THERAPY; FERRITIN BLOOD LEVEL; HUMAN; IRON BALANCE; IRON CHELATION; IRON STORAGE; LETTER; MONOTHERAPY; PRIORITY JOURNAL; THALASSEMIA;

ADULT; BETA-THALASSEMIA; CHELATION THERAPY; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; PYRIDONES;

EID: 77953759472     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08229.x     Document Type: Letter

References (10)

1. Aessopos, A., Kati, M., Farmaki, D., Polonifi, E., Deftereos, S. Tsironi, M. (2007) Intensive chelation therapy in β-thalassemia and possible adverse cardiac effects of desferrioxamine. International Journal of Haematology, 86, 212 215.
2. Farmaki, K., Tzoumari, I., Pappa, C., Chouliaras, G. Berdoukas, V. (2010) Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. British Journal of Haematology, 148, 466 475.
3. Kolnagou, A. Kontoghiorghes, G.J. (2006) Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin, 30, 239 249.
4. Kolnagou, A., Fessas, Ch., Papatryphonas, A., Economides, Ch. Kontoghiorghes, G.J. (2004) Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia. British Journal of Haematology, 127, 360 361.
5. Kolnagou, A., Economides, Ch., Eracleous, E. Kontoghiorghes, G.J. (2008a) Long term comparative studies in thalassaemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin, 32, 41 47.
6. Kolnagou, A., Michaelides, Y., Kontos, C., Kyriacou, K. Kontoghiorghes, G.J. (2008b) Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin, 32, 17 28.
7. Kolnagou, A., Yazman, D., Economides, C., Eracleous, E. Kontoghiorghes, G.J. (2009) Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol. Hemoglobin, 33, 312 322.
8. Kontoghiorghes, G.J. (1992) Advances in oral iron chelation in man. International Journal of Haematology, 55, 27 38.
9. Kontoghiorghes, G.J. (2009) A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassaemia and other transfused patients. Hemoglobin, 33, 332 338.
10. Kontoghiorghes, G.J., Kolnagou, A., Peng, C.T., Shah, S.V. Aessopos, A. (2010) Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opinion on Drug Safety, 9, 201 206.